retatrutide trial weight loss Lilly's triple agonist achieves 16.8% in phase 3 Retatrutide, an investigational triple hormone

Her commitment to delivering high-quality care, combined with her expertise in lifestyle medicine, ensures that patients receive the support and guidance they need throughout their weight loss journey

Activation of these receptors may reduce the hedonic drive to eat, the pleasure-seeking component of appetite that makes you want to eat even when you are not physically hungry

Additionally, they offer benefits like improved metabolism, cardiovascular health, and kidney health

GLP-1RAs have demonstrated significant anti-colorectal cancer activity [46], with the protective effects increasing in a duration-dependent manner

Your provider will confirm age requirements and current labeling details

It may interact with certain medications and isn't recommended during pregnancy or breastfeeding, as its effects aren't fully understood